Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more
SomaLogic tops off recent series A
Proteomics company SomaLogic Inc. added another $81 million to the crossover-heavy series A financing it disclosed in November, bringing the round’s total to $214 million. New investors in the second close include Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures, Boston Millennia Partners and Millennium Management. Casdin Capital led the round.
Ophthalmic disease play ONL raises $46.9M series B
ONL Therapeutics Inc. raised $46.9 million in a series B round to support completion of a Phase I study of lead candidate ONL1204 to treat retinal detachment and to start Phase Ib trials of the Fas inhibitor in open angle glaucoma and dry age-related macular degeneration. New investor Bios Partners led the round with participation from fellow new investors Johnson & Johnson Innovation – JJDC, Kaitai Capital, PSQ Capital and Michigan Capital Network Venture Fund III. Existing investors in round included ONL Therapeutics management, InFocus Capital Partners, ExSight Ventures, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Western Michigan University's Biosciences Research & Commercialization Center, and the Capital Community Angels...